Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapy

C. H. Granatek, K. Ezaki, Evan M Hersh, M. J. Keating, S. Rasmussen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A solid-phase radioimmunoassay was utilized to evaluate the antibody response of 21 acute myelogenous leukemia (AML) patients to active specific immunotherapy with either pooled allogeneic AML blast cells or leukemia-associated antigen (LAA), admixed with BCG cell-wall skeleton (CWS). Five of 13 patients treated with LAA had a significant antibody response to LAA after immunotherapy. Antibody response correlated with an increased remission duration (159+ vs. 75+ weeks) and an increased survival (164+ vs. 98+ weeks). Two of eight patients treated with cells responded to LAA, and three patients had initially high anti-LAA antibody levels. In the total study, eight of 11 patients surviving longer than 2 1/2 years and six of seven patients maintaining a complete remission longer than 2 years were antibody responders. Neither protocol induced significant antibody to a normal spleen extract, BCG-CWS, or a measles recall antigen. However, five of seven patients with initially high levels of antibody to BCG (following weekly BCG scarification) were long-term survivors. These data suggest that the humoral immune response to immunotherapeutic agents may be a useful parameter for monitoring immunotherapy of AML patients.

Original languageEnglish (US)
Pages (from-to)272-279
Number of pages8
JournalCancer
Volume47
Issue number2
DOIs
StatePublished - 1981
Externally publishedYes

Fingerprint

Immunotherapy
Antibody Formation
Leukemia
Mycobacterium bovis
Antigens
Cell Wall Skeleton
Acute Myeloid Leukemia
Antibodies
Active Immunotherapy
Measles
Humoral Immunity
Radioimmunoassay
Survivors
Spleen
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapy. / Granatek, C. H.; Ezaki, K.; Hersh, Evan M; Keating, M. J.; Rasmussen, S.

In: Cancer, Vol. 47, No. 2, 1981, p. 272-279.

Research output: Contribution to journalArticle

Granatek, C. H. ; Ezaki, K. ; Hersh, Evan M ; Keating, M. J. ; Rasmussen, S. / Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapy. In: Cancer. 1981 ; Vol. 47, No. 2. pp. 272-279.
@article{8e3b4fb28d424a37bf761b5212e18959,
title = "Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapy",
abstract = "A solid-phase radioimmunoassay was utilized to evaluate the antibody response of 21 acute myelogenous leukemia (AML) patients to active specific immunotherapy with either pooled allogeneic AML blast cells or leukemia-associated antigen (LAA), admixed with BCG cell-wall skeleton (CWS). Five of 13 patients treated with LAA had a significant antibody response to LAA after immunotherapy. Antibody response correlated with an increased remission duration (159+ vs. 75+ weeks) and an increased survival (164+ vs. 98+ weeks). Two of eight patients treated with cells responded to LAA, and three patients had initially high anti-LAA antibody levels. In the total study, eight of 11 patients surviving longer than 2 1/2 years and six of seven patients maintaining a complete remission longer than 2 years were antibody responders. Neither protocol induced significant antibody to a normal spleen extract, BCG-CWS, or a measles recall antigen. However, five of seven patients with initially high levels of antibody to BCG (following weekly BCG scarification) were long-term survivors. These data suggest that the humoral immune response to immunotherapeutic agents may be a useful parameter for monitoring immunotherapy of AML patients.",
author = "Granatek, {C. H.} and K. Ezaki and Hersh, {Evan M} and Keating, {M. J.} and S. Rasmussen",
year = "1981",
doi = "10.1002/1097-0142(19810115)47:2<272::AID-CNCR2820470211>3.0.CO;2-C",
language = "English (US)",
volume = "47",
pages = "272--279",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapy

AU - Granatek, C. H.

AU - Ezaki, K.

AU - Hersh, Evan M

AU - Keating, M. J.

AU - Rasmussen, S.

PY - 1981

Y1 - 1981

N2 - A solid-phase radioimmunoassay was utilized to evaluate the antibody response of 21 acute myelogenous leukemia (AML) patients to active specific immunotherapy with either pooled allogeneic AML blast cells or leukemia-associated antigen (LAA), admixed with BCG cell-wall skeleton (CWS). Five of 13 patients treated with LAA had a significant antibody response to LAA after immunotherapy. Antibody response correlated with an increased remission duration (159+ vs. 75+ weeks) and an increased survival (164+ vs. 98+ weeks). Two of eight patients treated with cells responded to LAA, and three patients had initially high anti-LAA antibody levels. In the total study, eight of 11 patients surviving longer than 2 1/2 years and six of seven patients maintaining a complete remission longer than 2 years were antibody responders. Neither protocol induced significant antibody to a normal spleen extract, BCG-CWS, or a measles recall antigen. However, five of seven patients with initially high levels of antibody to BCG (following weekly BCG scarification) were long-term survivors. These data suggest that the humoral immune response to immunotherapeutic agents may be a useful parameter for monitoring immunotherapy of AML patients.

AB - A solid-phase radioimmunoassay was utilized to evaluate the antibody response of 21 acute myelogenous leukemia (AML) patients to active specific immunotherapy with either pooled allogeneic AML blast cells or leukemia-associated antigen (LAA), admixed with BCG cell-wall skeleton (CWS). Five of 13 patients treated with LAA had a significant antibody response to LAA after immunotherapy. Antibody response correlated with an increased remission duration (159+ vs. 75+ weeks) and an increased survival (164+ vs. 98+ weeks). Two of eight patients treated with cells responded to LAA, and three patients had initially high anti-LAA antibody levels. In the total study, eight of 11 patients surviving longer than 2 1/2 years and six of seven patients maintaining a complete remission longer than 2 years were antibody responders. Neither protocol induced significant antibody to a normal spleen extract, BCG-CWS, or a measles recall antigen. However, five of seven patients with initially high levels of antibody to BCG (following weekly BCG scarification) were long-term survivors. These data suggest that the humoral immune response to immunotherapeutic agents may be a useful parameter for monitoring immunotherapy of AML patients.

UR - http://www.scopus.com/inward/record.url?scp=0019377109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019377109&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19810115)47:2<272::AID-CNCR2820470211>3.0.CO;2-C

DO - 10.1002/1097-0142(19810115)47:2<272::AID-CNCR2820470211>3.0.CO;2-C

M3 - Article

VL - 47

SP - 272

EP - 279

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -